ArticleJournal of gastrointestinal cancer2007

CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review.

Sheetal M Kircher et al.PubMed ↗Publisher ↗

No numbers read from the abstract.